CRML Shares Jump on Tanbreez Acceleration, But DeepValue Report Highlights Persistent Risks

What happened

Critical Metals Corp. announced an acceleration program for its Tanbreez rare-earth project, targeting first ore production by late 2028 or early 2029 and concentrate exports by Q3 2029 to de-risk development. The news drove a share price increase, reflecting market optimism about expanded drilling and engineering work funded to advance the project. However, the DeepValue master report rates CRML as a STRONG SELL, emphasizing that it remains pre-revenue with high execution risks, including unresolved Greenland permitting, non-binding EXIM funding, and lack of binding offtakes. The report assigns an 80% combined probability to base and bear scenarios with implied values of $6 to $11, below the current $13.17, citing a high likelihood of equity dilution and schedule slippage over the next 6-12 months. Despite the positive headline, this acceleration does not materially address core funding or permitting uncertainties, leaving the stock overvalued and vulnerable to downside.

Implication

The acceleration announcement may provide short-term momentum but does not de-risk critical elements like Greenland approvals or EXIM loan conversion, which are necessary for project viability. CRML's balance sheet shows going-concern warnings and limited cash, likely forcing future equity raises that could dilute shareholders and erode per-share value. Market sentiment is crowded and speculative, increasing volatility and the risk of sharp pullbacks if milestones slip or funding falters. The DeepValue report's base and bear scenarios imply a valuation range of $6 to $11, suggesting the current price of $13.17 embeds overly optimistic assumptions about timing and execution. Long-term investors should avoid new positions until concrete progress is made on binding offtakes, EXIM funding, and Greenland permitting, with a re-assessment window of 6-12 months.

Thesis delta

The acceleration news is a minor positive step but does not shift the STRONG SELL thesis, as it lacks material de-risking of financing, permitting, or commercial contracts. The core argument remains that CRML is overvalued with high execution risk, and investors should wait for a lower entry price after funding clarity or key milestone achievements. Until EXIM funding is secured, Greenland approvals are finalized, and offtakes turn binding, the downside risk outweighs potential upside.